NEW YORK, April 6, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced today that the Company's management and experts will present at multiple conference in April.
HemOnc Today Melanoma and Cutaneous Malignancies
- Date and Time: Friday, April 10, 2015, 5:10 PM ET
- Venue: Sheraton New York Times Square Hotel, New York, New York
- Website: www.healio.com/meeting/hemonctodaymelanoma/home
- Presenter: Dr. Robert O. Dillman, Vice President, Oncology
- Poster: INTUS: Randomized Phase III Trial of Patient-specific Therapeutic Vaccine (NBS20) in Patients Who Have Had Metastatic Melanoma
Crain's 'Business Of' Series: Life Sciences
- Date and Time: Wednesday, April 15, 2015, 8:30 AM – 10:00 AM ET
- Venue: John Jay College of Criminal Justice, New York, New York
- Website: http://www.crainsnewyork.com/events-calendar/details/4/3256496
- Panelist: Dr. Robin L. Smith, Executive Chairman
- Topic: Life Sciences, Economic Diversification and Job Growth
Needham & Company's 14th Annual Healthcare Conference
- Date and Time: Wednesday, April 15, 2015, 3:00 PM ET
- Venue: The Westin Grand Central Hotel, New York, New York
- Website: www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx
- Presenter: Dr. David Mazzo, Chief Executive Officer
- Topic: Company Presentation
- Webcast: www.neostem.com/investors/investor-events/
American Association for Cancer Research Annual Meeting
- Date and Time: Wednesday, April 22, 2015, 8:00 AM ET
- Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania
- Website: www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=25#.VRVYm0ahyio
- Presenter: Dr. Andrew N. Cornforth, Manufacturing Director
- Poster: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma
Interphex
- Date and Time: Wednesday, April 22, 2015, 2:00 PM ET
- Venue: Jacob Javits Center, New York, New York
- Website: www.interphex.com
- Presenter: Dr. Robert Preti, Chief Scientific Officer
- Topic: Development by Design: A Strategy to Support Commercial Success
Stem Cell Summit 2015
- Date and Time: Tuesday, April 28, 2015, 4:05 PM ET
- Venue: Hyatt Regency, Boston, Massachusetts
- Website: www.gtcbio.com/conferences/stem-cell-summit-agenda
- Presenter: Dr. Hans Keirstead, President, NeoStem Oncology
- Topic: Immunotherapy – Revolution in Cancer
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based personalized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immune-oncology, ischemic repair and immunomodulation) with a lead, late-stage clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's contract development and manufacturing business as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.